var data={"title":"Technetium Tc-99m sulfur colloid: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Technetium Tc-99m sulfur colloid: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/383930?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21982565\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Radiopharmaceutical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21988382\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer lymph node localization:</b> SubQ: 0.1 to 1 mCi (3.7 to 37 MBq) in volumes ranging from 0.1 to 1 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malignant melanoma lymph node localization:</b> SubQ: 0.1 to 1 mCi (3.7 to 37 MBq) in volumes ranging from 0.1 to 1 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peritoneo-venous (LeVeen) shunt patency evaluation:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intraperitoneal injection: 1 to 3 mCi (37 to 111 MBq)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Percutaneous transtubal (efferent limb) injection: 0.3 to 1 mCi (12 to 37 MBq) in a maximum volume of 0.5 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reticuloendothelial cell imaging:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Bone marrow:</i> IV: 3 to 12 mCi (111 to 444 MBq)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Liver/spleen:</i> IV: 1 to 8 mCi (37 to 296 MBq)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Esophageal transit studies, gastroesophageal reflux scintigraphy, pulmonary aspiration imaging:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Gastroesophageal studies:</i> Oral: 0.15 to 0.3 mCi (5.55 to 11.1 MBq)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pulmonary aspiration studies:</i> Oral: 0.3 to 0.5 mCi (11.1 to 18.5 MBq)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21988381\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reticuloendothelial cell imaging:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Bone marrow:</i> Pediatrics: IV: 0.03 to 0.15 mCi/<b>kg</b> (1.11 to 5.55 MBq/<b>kg</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Liver/spleen:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Newborn Infants: IV: 0.2 to 0.5 mCi (7.4 to 18.5 MBq)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: IV: 0.015 to 0.075 mCi/<b>kg</b> (0.56 to 2.78 MBq/<b>kg</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Esophageal transit studies, gastroesophageal reflux scintigraphy, pulmonary aspiration imaging:</b> <i>Gastroesophageal studies or pulmonary aspiration studies:</i> Pediatrics: Oral or nasogastric tube: 0.1 to 0.3 mCi (3.7 to 11.1 MBq)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21988384\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22046420\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22046421\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46170894\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: Contents to be combined with Technetium Tc 99m pertechnetate sodium (not included)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21982564\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21988385\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Route of administration varies by indication. Agitate the vial/syringe (carefully) immediately prior to administration to avoid particle aggregation and to assure uniform radioactivity distribution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Breast cancer or malignant melanoma, lymph node localization: Administer SubQ; used in conjunction with a handheld gamma counter to identify nodes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneo-venous (LaVeen) shunt patency evaluation: Administer either by intraperitoneal injection or by percutaneous transtubal (efferent limb; maximum volume of 0.5 mL) injection. Consider patient repositioning or other measures to help assure uniform radiopharmaceutical mixing with the peritoneal fluid.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reticuloendothelial cell imaging: Administer IV</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastroesophageal imaging studies and pulmonary aspiration studies:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Administer orally.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatrics: Administer orally or by nasogastric tube; for oral administration, combine with a milk feeding; for nasogastric administration, administer into stomach, then instill a normal volume of dextrose or milk feeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">To facilitate GI reflux imaging, consider administering by nasogastric tube.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Radiopharmaceutical; use appropriate precautions for handling and disposal. Use waterproof gloves and effective radiation shielding when handling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7734628\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Imaging agent:</b> Localization of lymph nodes draining a primary tumor in patients with breast cancer or malignant melanoma (when used with a handheld gamma counter); reticuloendothelial cell function imaging agent (liver, spleen, bone marrow); evaluation of peritoneo-venous (LeVeen) shunt patency; esophageal transit studies, gastroesophageal reflux scintigraphy, detection of pulmonary aspiration of gastric contents</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7734624\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22464255\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiorespiratory arrest, flushing, hypotension, localized blanching</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, dizziness, numbness, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, pruritus, scarring (injection site), skin rash, skin sclerosis (injection site), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactic shock, anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Burning sensation at injection site, erythema at injection site, swelling at injection site, tissue necrosis at injection site (eschar)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21983082\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21987473\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Anaphylactic reactions (bronchospasm, hypotension, urticarial), with rare fatalities have occurred. Medications, equipment, and personnel for management of hypersensitivity reactions should be available during administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: Radiation-emitting products may increase the risk for cancer, particularly in children. Use the smallest dose necessary and ensure safe handling to protect patients and healthcare workers. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary accumulation: Technetium Tc 99m sulfur colloid is physically unstable; particles may settle with exposure/time. Following IV administration, larger particles may be trapped by the pulmonary capillary bed, resulting in uneven distribution of radioactivity. Agitate vial adequately prior to administration to avoid particle aggregation and nonuniform distribution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. <b>Note:</b> Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastroesophageal imaging: May consider administering via nasogastric tube to facilitate imaging for gastroesophageal reflux.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lymph node localization: Tracers are intended to supplement palpation, visual inspection, and other traditional lymph node localization procedures. Node localization is dependent on underlying lymphatic system patency and structure, reticuloendothelial cell function within nodes, and the radiopharmaceutical injection technique. Distortion by prior surgery, radiation therapy, or metastatic disease may result in failure to localize nodes. Technetium Tc 99m sulfur colloid, like other tracers, may not localize all nodes; tracers may differ in extent of lymph node localization.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peritoneal clearance: Following intraperitoneal administration, tracer mixes with peritoneal fluid; clearance from peritoneal cavity (into systemic circulation) varies depending on shunt patency; concentrates in the liver following transfer to systemic circulation. Obtain serial images of shunt and liver. An adequate evaluation of complete versus partial shunt blockage may not be possible. Transperitoneal absorption may occur, although it would be slow. The most definitive evaluation of both shunt and liver/spleen is generally obtained within 3 hours after intraperitoneal injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Reticuloendothelial cell imaging: Altered biodistribution with lung and soft tissue uptake (instead of reticuloendothelial system) has been observed after IV administration. Biodistribution and reticuloendothelial uptake may be determined by particle size and physical-chemical properties formed during preparation. Diseases affecting the reticuloendothelial system may also affect uptake.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22194916\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22194914\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=91064&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21983078\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21983079\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Unbound technetium crosses the placenta. Technetium Tc 99m can be detected in fetal tissue; the amount depends upon the specific formulation, route of administration, and stage of pregnancy (Adelstein 1999).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (Adelstein 1999; ICRP 2000; Parker 2004). Pregnancy status should be determined in women of childbearing potential (Parker 2004). The manufacturer recommends that in women of reproductive potential, pregnancy status should be assessed 48 prior to administration or imaging procedure should be performed within 10 days following the onset of menses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21983081\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Technetium Tc 99m is excreted into breast milk; information specific to technetium Tc 99m sulfur colloid has not been located. Based on clearance, the manufacturer recommends that patients should pump and discard breast milk for at least 6 hours after administration. Following higher dose (&gt;370 MBq) procedures, the manufacturer recommends avoiding close contact with infants for 6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Following the administration of a radiopharmaceutical, women with a well-established milk supply should pump at normal feeding times and discard the milk until breastfeeding may be resumed (Harding 1995; Mountford 1989). Excretion of technetium Tc 99m into colostrum is widely variable and information is limited; therefore, recommendations related to early breastfeeding cannot be made (Mountford 1989; Rubow 1994). Elective diagnostic procedures should be delayed until breastfeeding has stopped (Parker 2004). Depending on the dose, compliance with regulatory requirements for instructions to the patient and recordkeeping may also be applicable (US NRC 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21988391\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Pregnancy test (48 prior to administration if imaging procedure is not performed within 10 days following the onset of menses). Monitor for signs/symptoms of hypersensitivity reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21988368\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Radioactive diagnostic agent which decays by isomeric transition to emit a photon that can be detected by imaging. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21988370\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;\">Distribution: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intraperitoneal: Distributed to the peritoneal fluid</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Distributed to the reticuloendothelial system </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Distributed through the gastrointestinal tract</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: Distributed to lymphatic capillaries and then to the lymph nodes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Half-life, nominal: IV: ~2.5 minutes; Half-life, physical: 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Oral: Feces (primarily)</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adelstein SJ. Administered radionuclides in pregnancy. <i>Teratology</i>, 1999, 59(4):236-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-sulfur-colloid-drug-information/abstract-text/10331526/pubmed\" target=\"_blank\" id=\"10331526\">10331526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harding LK, Bossuyt S, Pellet C, et al. Recommendations for nuclear medicine physicians regarding breastfeeding mothers. <i>Eur J Nucl Med</i>, 1995, 22(5)BP17.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    International Commission on Radiological Protection (ICRP). Pregnancy and medical radiation. <i>Ann ICRP</i>, 2000, 30(1):iii-viii, 1-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-sulfur-colloid-drug-information/abstract-text/11108925/pubmed\" target=\"_blank\" id=\"11108925\">11108925</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mountford PJ, Coakley AJ, &quot;A review of the secretion of radioactivity in human breast milk: data, quantitative analysis and recommendations. <i>Nucl Med Commun</i>, 1989, 10(1):15-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-sulfur-colloid-drug-information/abstract-text/2645546/pubmed\" target=\"_blank\" id=\"2645546\">2645546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker JA, Daube-Witherspoon ME, Graham LS, et al. Procedure guideline for general imaging: 3.0. Society of Nuclear Medicine, 2004. Available at http://interactive.snm.org/docs/General_Imaging_v3.0.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubow S, Klopper J, Wasserman H, et al. The excretion of radiopharmaceuticals in human breast milk: additional data and dosimetry. <i>Eur J Nucl Med</i>, 1994, 21(2):144-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-sulfur-colloid-drug-information/abstract-text/8162938/pubmed\" target=\"_blank\" id=\"8162938\">8162938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Technetium Tc 99m Sulfur Colloid Kit [prescribing information]. Billerica, MA: Pharmalucence, Inc.; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U.S. Nuclear Regulatory Commission (USNRC), &quot;Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials,&quot; 1997.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 91064 Version 27.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F21982565\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F21988382\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F21988381\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F21988384\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22046420\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22046421\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F46170894\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F21982564\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F21988385\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F7734628\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7734624\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F22464255\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F21983082\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F21987473\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F22194916\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F22194914\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F21983078\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F21983079\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21983081\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F21988391\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F21988368\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F21988370\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/91064|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}